Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

2.

Correlation between estimates of tumor perfusion from microbubble contrast-enhanced sonography and dynamic contrast-enhanced magnetic resonance imaging.

Yankeelov TE, Niermann KJ, Huamani J, Kim DW, Quarles CC, Fleischer AC, Hallahan DE, Price RR, Gore JC.

J Ultrasound Med. 2006 Apr;25(4):487-97.

PMID:
16567438
3.

Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.

Armbruster M, Sourbron S, Haug A, Zech CJ, Ingrisch M, Auernhammer CJ, Nikolaou K, Paprottka PM, Rist C, Reiser MF, Sommer WH.

Invest Radiol. 2014 Jan;49(1):7-14. doi: 10.1097/RLI.0b013e3182a4eb4a.

PMID:
24002080
4.

Antivascular ultrasound therapy: magnetic resonance imaging validation and activation of the immune response in murine melanoma.

Hunt SJ, Gade T, Soulen MC, Pickup S, Sehgal CM.

J Ultrasound Med. 2015 Feb;34(2):275-87. doi: 10.7863/ultra.34.2.275.

PMID:
25614401
5.

Sonographic depiction of microvessel perfusion: principles and potential.

Fleischer AC, Niermann KJ, Donnelly EF, Yankeelov TE, Canniff KM, Hallahan DE, Rothenberg ME.

J Ultrasound Med. 2004 Nov;23(11):1499-506. Review.

PMID:
15498915
6.

Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms.

Armbruster M, Zech CJ, Sourbron S, Ceelen F, Auernhammer CJ, Rist C, Haug A, Singnurkar A, Reiser MF, Sommer WH.

J Magn Reson Imaging. 2014 Aug;40(2):457-66. doi: 10.1002/jmri.24363. Epub 2013 Dec 18.

PMID:
24347148
7.

Clinical utility of multimodality imaging with dynamic contrast-enhanced MRI, diffusion-weighted MRI, and 18F-FDG PET/CT for the prediction of neck control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation.

Ng SH, Lin CY, Chan SC, Lin YC, Yen TC, Liao CT, Chang JT, Ko SF, Wang HM, Chang CJ, Wang JJ.

PLoS One. 2014 Dec 22;9(12):e115933. doi: 10.1371/journal.pone.0115933. eCollection 2014.

8.

Dynamic contrast-enhanced MR imaging predicts local control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy.

Ng SH, Lin CY, Chan SC, Yen TC, Liao CT, Chang JT, Ko SF, Wang HM, Huang SF, Lin YC, Wang JJ.

PLoS One. 2013 Aug 7;8(8):e72230. doi: 10.1371/journal.pone.0072230. eCollection 2013.

9.

Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer.

Eby PR, Partridge SC, White SW, Doot RK, Dunnwald LK, Schubert EK, Kurland BF, Lehman CD, Mankoff DA.

Acad Radiol. 2008 Oct;15(10):1246-54. doi: 10.1016/j.acra.2008.03.019.

10.

Correlation Between F-18 Fluorodeoxyglucose Positron Emission Tomography Metabolic Parameters and Dynamic Contrast-Enhanced MRI-Derived Perfusion Data in Patients with Invasive Ductal Breast Carcinoma.

Kim TH, Yoon JK, Kang DK, Lee SJ, Jung YS, Yim H, An YS.

Ann Surg Oncol. 2015 Nov;22(12):3866-72. doi: 10.1245/s10434-015-4526-z. Epub 2015 Mar 25.

PMID:
25805237
11.

Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.

Partridge SC, Vanantwerp RK, Doot RK, Chai X, Kurland BF, Eby PR, Specht JM, Dunnwald LK, Schubert EK, Lehman CD, Mankoff DA.

J Magn Reson Imaging. 2010 Nov;32(5):1124-31. doi: 10.1002/jmri.22362.

12.

Tumor metabolism and perfusion ratio assessed by 18F-FDG PET/CT and DCE-MRI in breast cancer patients: Correlation with tumor subtype and histologic prognostic factors.

An YS, Kang DK, Jung YS, Han S, Kim TH.

Eur J Radiol. 2015 Jul;84(7):1365-70. doi: 10.1016/j.ejrad.2015.03.026. Epub 2015 Mar 30.

PMID:
25886700
13.

Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.

Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, Daisaki H, Macapinlac HA.

Radiology. 2012 Apr;263(1):53-63. doi: 10.1148/radiol.12111177.

PMID:
22438441
14.

Correlation of quantified contrast-enhanced sonography with in vivo tumor response.

Hwang M, Hariri G, Lyshchik A, Hallahan DE, Fleischer AC.

J Ultrasound Med. 2010 Apr;29(4):597-607.

PMID:
20375378
15.

Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging.

Vucic E, Dickson SD, Calcagno C, Rudd JH, Moshier E, Hayashi K, Mounessa JS, Roytman M, Moon MJ, Lin J, Tsimikas S, Fisher EA, Nicolay K, Fuster V, Fayad ZA.

JACC Cardiovasc Imaging. 2011 Oct;4(10):1100-9. doi: 10.1016/j.jcmg.2011.04.020.

16.

Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins.

Meier R, Braren R, Kosanke Y, Bussemer J, Neff F, Wildgruber M, Schwarzenböck S, Frank A, Haller B, Hohlbaum AM, Schwaiger M, Gille H, Rummeny EJ, Beer AJ.

PLoS One. 2014 May 6;9(5):e94972. doi: 10.1371/journal.pone.0094972. eCollection 2014.

17.

Brain tumor perfusion: comparison of dynamic contrast enhanced magnetic resonance imaging using T1, T2, and T2* contrast, pulsed arterial spin labeling, and H2(15)O positron emission tomography.

Lüdemann L, Warmuth C, Plotkin M, Förschler A, Gutberlet M, Wust P, Amthauer H.

Eur J Radiol. 2009 Jun;70(3):465-74. doi: 10.1016/j.ejrad.2008.02.012. Epub 2008 Mar 24.

PMID:
18359598
18.

Variability of target and normal structure delineation using multimodality imaging for radiation therapy of pancreatic cancer.

Dalah E, Moraru I, Paulson E, Erickson B, Li XA.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):633-40. doi: 10.1016/j.ijrobp.2014.02.035. Epub 2014 Apr 20.

PMID:
24755533
19.

Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?

Weber MA, Henze M, Tüttenberg J, Stieltjes B, Meissner M, Zimmer F, Burkholder I, Kroll A, Combs SE, Vogt-Schaden M, Giesel FL, Zoubaa S, Haberkorn U, Kauczor HU, Essig M.

Invest Radiol. 2010 Dec;45(12):755-68. doi: 10.1097/RLI.0b013e3181ec9db0.

PMID:
20829706
20.

Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors.

Abramyuk A, Wolf G, Shakirin G, Haberland U, Tokalov S, Koch A, Appold S, Zöphel K, Abolmaali N.

Acta Radiol. 2010 Sep;51(7):793-9. doi: 10.3109/02841851.2010.491092.

PMID:
20583948

Supplemental Content

Support Center